Bent U. Frandsen
Thank you very much, Michael. And welcome everybody to ExpreS2ion. Q3 2026 result webcast. I am the CEO of the company, and I am joined today by our CFO, Keith Alexander. I will begin with our operational and clinical progress, including our platform partnerships. And the latest update on ES2B-C001. Our HER2-targeting breast cancer immunotherapy. And then Keith will take us through the third quarter and nine months financial results before we open for questions. Before we begin, please note the disclaimer on this slide. Today's presentation includes forward-looking statements, particularly on clinical development, partnering, and funding. These reflect our current expectations and are subject to risks and uncertainties, so actual outcomes and timing may differ. Let me start with three reasons why this is an important period for ExpreS2ion. First, we have observed anti-HER2 antibody responses in 12 out of 13 evaluable patients in our Phase I clinical trial. These are preliminary findings, but they support the biological rationale for ES2B-C001, second, in the market. There is still a substantial need for more durable disease control. Even with the strong results reported for newer first-line HER2 combinations, around 3 in 10 patients have progressed or passed away within two years. And third, our Phase I primary readout is expected in the first quarter of 2027. That dataset, together with the translational work, will be central to our partnering discussions and the next development decision. Our pipeline has a clear focus on one proprietary oncology lead asset supported by a broader group of partnered infectious disease programs; we sponsor ES2B-C001 ourselves. Our malaria, Nipah virus, and influenza activities are advanced through licenses, academic collaborations, and grant funding with different levels of funding coverage. This structure allows us to focus our own investment on oncology, while continuing to demonstrate the capabilities of the ExpreS2ion platform across other applications. The pipeline chart also shows the historical COVID-19 program, which reached phase three before Bavarian Nordic discontinued it for commercial reasons. I will now move more in-depth into our platform. So ExpreS2 is the protein expression platform behind our programs since 2010. It has been used to express more than 500 proteins and virus-like particles, with a success rate above 90%. Its clinical track record includes the COVID-19 program, whose Phase III study enrolled more than 4,200 participants and met its primary endpoint, demonstrating non-inferiority against a commercial mRNA vaccine. Published work demonstrated production of more than 400mg of RH5.1 antigen from a single 25-liter cGMP batch, which demonstrates solid experience in this field. For ExpreS2, this platform supports several sources of income and funding: technology licenses, contract research, and grant-funded programs. The Serum Institute of India Malaria Agreement from November 2025 is an important example. Glycan engineering patent applications published this year also extended our intellectual property estate. In malaria, our platform produces four antigens for the University of Oxford. Development programmes at RH5.1 and R78C are particularly relevant commercially because they are licensed to the Serum Institute of India. During the quarter, a Phase IIb trial of RH5.1 concluded, as did the Phase Ib/II trial combining RH5.1 and R78C. Two new trials involving combinations with the W.H.O. recommended R21 vaccine are being prepared, and further Phase IIb completion is expected in the fourth quarter. Several important data sets are expected in the first quarter of 2027, including longer-term RH5.1 follow-up and combination data. The University of Oxford determines the timing, which may change. The need remains very large. Still, more than 600,000 died from malaria in 2024, mostly among young children in Africa. For us, the Serum Institute of India license offers potential milestones and royalties as development and commercialization progress, as we announced in November 2025. The other Oxford programs provide additional clinical experience with our platform. Nipah is another important application for our platform. Recurring outbreaks, high fatality rates, and the absence of an approved vaccine underscore the need for a preventive option. Underline the need for a preventive option during Q3 work. Continue to finalize the cGMP-ready antigen process, and cGMP manufacturing is underway at Northway Biotech. The next steps are the toxicology study, the clinical trial application, and a Phase I/IIa trial run by the consortium. The program is grant-funded to Phase I and combines ExpreS2-produced antigen with VLP technology, the same overall approach used for ES2B-C001 cancer immunotherapy and the Covid-19 vaccine. Because that antigen is made with ExpreS2, we expect our technology to form part of any future licensing agreement, although no such outcome is assured. We expect our technology to form part of any future licensing agreement, although no such outcome is assured. MucoVax, meanwhile, is approximately 67% grant-funded. It's work on cell lines. Large-scale antigen production will be key. Purification also contributes to the platform's capabilities. Let me turn to ES2B-C001, our lead asset, and explain where we believe active immunotherapy could contribute to the treatment of HER2-expressing cancers. Treatment for HER2-positive metastatic breast cancer has advanced considerably. Antibody-drug conjugates, or ADCs, have raised the standard that new approaches must meet, as seen in the DESTINY-Breast09 trial of trastuzumab deruxtecan. Enhertu, also known as fam-trastuzumab deruxtecan, delivered a median progression-free survival of around 41 months. Nevertheless, around 30% of patients had progressed or passed away by two years. That remaining gap is relevant to our development strategy. ES2B-C001 is designed to add an active, broad anti-HER2 immune response to standard treatment with the aim of extending disease control. We see it as a potential complement to existing therapies, including ADCs. The historical comparisons on this slide illustrate progress in the field, though not head-to-head comparisons across trials, and the intended benefit of adding ES2B-C001, of course, still needs to be tested clinically. Our current study is establishing safety and immune responses. ES2B-C001 combines the full extracellular part of HER2 produced using ExpreS2 with high-density display on a virus-like particle. That extracellular region contains four domains. Individual HER2-directed. Monoclonal antibodies bind to specific sites. By presenting all four domains, ES2B-C001 is designed to stimulate a broader family of antibodies against HER2. One is designed to stimulate a broader family of antibodies against HER2. The VLP provides a repetitive display intended to help the immune system generate a strong and lasting response. There is established experience with durable antibody responses to VLP-based infectious disease vaccines, for example with HPV vaccines. That experience supports the rationale for our design. Our own Phase I follow-up and planned maintenance boosters are intended to address these questions alongside translational analyses of antibody quality and function. Turning to the clinical data. This is an open-label, Phase I dose-escalation study in patients with advanced HER2-positive or HER2-low breast cancer after standard treatment. It evaluates five intramuscular doses across three cohorts: 50, 150, and 450 micrograms. The main objectives are safety, tolerability, and immunogenicity. 19 patients have been dosed in the preliminary evaluable dataset. 12 of 13 patients showed at least a two-fold increase in anti-HER2 antibody titers. Looking at the graph, titers rise over the dosing series and then decline gradually after the fifth dose. Individual patterns varied, and the graph uses a data cutoff of October 5th. Follow-up and planned boosters will help us understand how these responses can be maintained, and we continue to monitor safety. No dose-limiting toxicities and no treatment-related serious adverse events have been reported in the data presented here. The Independent Safety Monitoring Board has cleared continuation. These are encouraging early observations, but the study is small and findings remain preliminary. This translational work will examine immune quality, durability, and mode of action, together with the primary readout expected in Q1 2027. This should provide a more complete basis for deciding how to take this to ES2B-C001 forward. Our immediate priorities are to complete Phase I dosing in the fourth quarter. Obtain translational results. Obtain translational results around the end of the year, and deliver the primary Phase I readout in the first quarter of 2027. For Phase II, the proposed focus is first-line HER2-positive metastatic breast cancer. Informed by our Scientific Advisory Board discussions. This would give us a more homogeneous population with better-preserved immune function than in a heavily pretreated setting. We are planning a focused study of 80 to 120 patients. The intention is to use one standard of care backbone across all arms, so we can assess the contribution of ES2B-C001 within a standard of care setting. The proposed main readout is progression-free survival at 24 months. Tumor-informed circulating tumor DNA, or ctDNA, is planned as a key secondary endpoint, providing another way to follow disease activity alongside clinical assessments. The design remains subject to protocol finalization, statistical validation, and regulatory interaction. The dose arms are not yet fixed. A 24-month endpoint also requires sufficient patient follow-up. The eventual readout date will depend on recruitment and the final study design. Our preferred partnering model is for the partner to fund Phase II and collaborate on development, with an option to license after interim data. This is a model we are pursuing with a partner. We are targeting a Phase II start in the second half of 2027, subject to funding and other development requirements.
That concludes my operational and clinical update. I will now hand over to Keith to take us through the Q3 and nine months 2026 financial results. Keith, over to you.